Adaptive Biotechnologies Corporation reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $93.973 million for the three months ended September 30, 2025, compared to $46.435 million in the same period last year, marking a 102% increase. For the nine months ended September 30, 2025, revenue was $205.295 million, up from $131.498 million in the prior year. The company achieved a net income of $9.546 million for the third quarter, a notable turnaround from a net loss of $32.071 million in the same quarter of 2024. However, for the nine-month period, the company still reported a net loss of $45.920 million, although this was an improvement from a loss of $125.800 million in the previous year.
The substantial revenue growth was primarily driven by a 52% increase in Minimal Residual Disease (MRD) revenue, which totaled $56.788 million, and a significant rise in collaboration revenue from the Immune Medicine segment, largely attributed to the termination of the Genentech Agreement. The company recognized $33.742 million in collaboration revenue during the third quarter, compared to just $3.512 million in the same period last year. The clonoSEQ test volume also increased by 38%, with 27,111 tests delivered in the third quarter of 2025, up from 19,600 tests in the prior year.
In terms of operational metrics, Adaptive Biotechnologies reported a total of 152.581 million shares outstanding as of September 30, 2025, an increase from 147.774 million shares at the end of 2024. The company’s cash and cash equivalents, along with marketable securities, stood at $216.8 million, down from $256.0 million at the end of 2024. The decrease in cash was primarily due to cash used in operating activities, which amounted to $48.041 million for the nine months ended September 30, 2025, a reduction from $82.721 million in the same period of 2024.
Strategically, the company has focused on enhancing its MRD and Immune Medicine business areas. The termination of the Genentech Agreement, effective February 9, 2026, has allowed Adaptive to recognize previously deferred revenue, although it may impact future collaboration revenue. The company has also integrated its clonoSEQ test into electronic medical record systems to facilitate easier test ordering, which is expected to enhance customer engagement and adoption rates.
Looking ahead, Adaptive Biotechnologies anticipates continued growth in its MRD revenue as it expands its clinical testing volume and optimizes payor coverage. However, the company expects some fluctuations in its Immune Medicine revenue due to the recent changes in its collaboration agreements. Overall, management remains optimistic about leveraging its immune medicine platform to drive future growth and innovation in the diagnosis and treatment of diseases.
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation develops immune medicine products leveraging proprietary next-generation sequencing and machine learning to decode the adaptive immune system. Its core offerings include clonoSEQ, an FDA-authorized assay for detecting minimal residual disease (MRD) in lymphoid cancers, serving clinicians and biopharmaceutical partners. The company also advances immune-based therapies for cancer and autoimmune diseases through its extensive immunosequencing platform, large clinical database, and collaborations with pharmaceutical firms.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.